Relationships between drug sponsors and investigative sites have become more effective during the past two years, according to a new CenterWatch survey, as the initiatives top sponsors have implemented in recent years to address site burdens—such as increased protocol complexity and insufficient study support—are beginning to have a positive impact.
Patient reported outcomes take center stage
A growing number of clinical trials now are going beyond conventional randomized control measurements to collect self-reported outcomes from patients—focusing on improving patients’ involvement by including their perspectives throughout the drug development process. But while interest in developing and applying patient-reported outcomes (PROs) across the drug development and post-market spectrum is growing—among sponsors, clinicians, payers, regulators and patients—progress has been slow.
To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.
